X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi’s Synthorin™ technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors.
Lead Product(s): THOR-707,Pembrolizumab
Therapeutic Area: Oncology Product Name: THOR-707
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Synthorx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
The Phase 2 clinical trial aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of THOR-707, a highly differentiated non-alpha IL-2 candidate combined with or in sequenced administration with MSD’s KEYTRUDA® (pembrolizumab) in patients with various cancers.
Lead Product(s): THOR-707,Pembrolizumab
Therapeutic Area: Oncology Product Name: THOR-707
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 29, 2020
Details:
Under the terms and conditions of the deal, Synthorx’ lead candidate THOR-707 is being tested against multiple tumour types, and will also be tested in combination with Sanofi’s own cancer drugs.
Lead Product(s): THOR-707
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,500.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
